Is This a Sign Pfizer's Aggressive Growth Strategy Is Paying Off?

Did you know that from 2022 to 2025, Pfizer (NYSE: PFE)'s top line declined by a mammoth 38%? Its revenue fell from more than $101 billion when its COVID vaccine and pill were in high demand to less than $63 billion last year, as the company has been battling some sizable headwinds. Unsurprisingly, the stock has also taken a beating; in five years, it has declined by around 35%.Pfizer has been working on ways to expand its growth prospects, as it faces even more challenges ahead as key products lose patent protection in the near future, which may further drive down revenue. The company has been loading up on acquisitions in recent years in an effort to build up its portfolio and strengthen its top line. Its latest quarterly results may suggest that the business is indeed going in the right direction.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool